Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Sumitomo Dainippon Pharma says it has initiated a Phase I clinical study in Japan of DSP-1181, a treatment for obsessive-compulsive disorder that was created using artificial intelligence technology from Exscientia. A joint research team combined Sumitomo’s expertise in monoamine GPCR drug discovery and Exscientia’s Centaur Chemist AI platform. The firms say they completed the exploratory research phase in less than 12 months, versus the typical average of 4.5 years.
This article has been sent to the following recipient: